A multi-centre prospective study of febrile neutropenia in Norway: Microbiological findings and antimicrobial susceptibility

References

• Bodey GP, Sathe YS, Freireich EJ. Quantitative relationship between circulating leukocytes and infection in patients with acute leukaemia. Ann Int Med 1966; 64: 328–40
   PubMed Web of Science ®Google Scholar
• Bille J. Laboratory diagnosis of infections in febrile neutropenic or immunocompromized patients. Int J Antimicrob Agents 2000; 16: 87–9
   PubMed Web of Science ®Google Scholar
• Viscoli C. The evolution of the empirical management of fever and neutropenia in cancer patients. J Antimicrob Chemother 1998; 41((Suppl D))65–80
   PubMed Web of Science ®Google Scholar
• Oppenheim BA. The changing pattern of infection in neutropenic patients. J Antimicrob Chemother 1998; 41((Suppl D))7–11
   PubMed Web of Science ®Google Scholar
• Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 1998; 41((Suppl D))13–24
   PubMed Web of Science ®Google Scholar
• EORTC, Schimpff SC, Gaya H, Klastersky J, Tattersall MH, Zinner SH. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC International Antimicrobial Therapy Project Group. J Infect Dis 1978; 137: 14–29
   PubMedGoogle Scholar
• EORTC. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Ann Intern Med 1993; 119: 584–93
   PubMed Web of Science ®Google Scholar
• EORTC. Gram-positive bacteraemia in granulocytopenic cancer patients. EORTC International Antimicrobial Therapy Cooperative Group. Eur J Cancer 1990; 26: 569–74
   PubMedGoogle Scholar
• Klastersky J, Glauser MP, Schimpff SC, Zinner SH, Gaya H. Prospective randomized comparison of 3 antibiotic regimens for empirical therapy of suspected bacteraemic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother 1986; 29: 263–70
   PubMed Web of Science ®Google Scholar
• EORTC. Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteraemia in cancer patients with granulocytopenia. The EORTC International Antimicrobial Therapy Cooperative Group. N Engl J Med 1987; 317: 1692–8
   PubMed Web of Science ®Google Scholar
• Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empirical therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 1995; 39(2)445–52
   PubMed Web of Science ®Google Scholar
• Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R, Del Favero A, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother 1996; 40(5)1108–15
   PubMed Web of Science ®Google Scholar
• Tangen JM, Berentsen S, Dahl IM, Ly B, Myrvang B. Empirical antibiotic treatment of patients with acute myelogenous leukaemia. Tidsskr Nor Laegeforen 1999; 119: 35–8
   PubMedGoogle Scholar
• Hammerstrom J, Jacobsen T. Bacteraemia with granulocytopenia: microbiology and empirical antibiotic treatment. Tidsskr Nor Laegeforen 1998; 118: 4370–5
   PubMedGoogle Scholar
• Leegaard TM, Vik E, Caugant DA, Froholm LO, Hoiby EA. Low occurrence of antibiotic resistance in Escherichia coli and staphylococci isolated from blood cultures in 2 Norwegian hospitals in 1991–92 and 1995–96. Apmis 1999; 107: 1060–8
   PubMed Web of Science ®Google Scholar
• Leegaard TM, Bevanger L, Jureen R, Lier T, Melby KK, Caugant DA, et al. Antibiotic sensitivity still prevails in Norwegian blood culture isolates. Int J Antimicrob Agents 2001; 18(2)99–106
   PubMed Web of Science ®Google Scholar
• Digranes A, Solberg CO, Sjursen H, Skovlund E, Sander J. Antibiotic susceptibility of blood culture isolates of Enterobacteriaceae from 6 Norwegian hospitals 1991–1992. Apmis 1997; 105: 854–60
   PubMed Web of Science ®Google Scholar
• Digranes A. Antibiotic susceptibility of blood culture isolates of Enterobacteriaceae. Apmis 2001; 109: 641–6
   PubMed Web of Science ®Google Scholar
• Kruse, H, Simonsen, GS. NORM/NORM-VET 2000. Consumption of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway. Tromsø/Oslo 2002. ISSN: 1502-2307, 2001; 1–65.
   Google Scholar
• Ronnestad A, Abrahamsen TG, Gaustad P, Finne PH. Antibiotic susceptibility of blood culture isolates after nearly 2 decades with netilmicin and ampicillin in neonatal septicaemia. Apmis 1999; 107: 257–62
   PubMed Web of Science ®Google Scholar
• Kruse, H, Simonsen, GS. NORM/NORM-VET 2001. Consumption of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway. Tromsø/Oslo, 2002:1–73.
   Google Scholar
• Closs O, Digranes A. rapid identification of prompt lactose-fermenting genera within the family Enterobacteriaceae. Acta Pathol Microbiol Scand [B] Microbiol Immunol 1971; 79: 673–8
   PubMedGoogle Scholar
• Cowan S. Cowan and Steel's manual for identification of medical bacteria2nd edn. Cambridge University Press, CambridgeUK 1974
   Google Scholar
• Lassen J. Rapid identification of Gram-negative rods using a 3-tube method combined with a dichotomic key. Acta Pathol Microbiol Scand Suppl 1975; 83: 525–33
   PubMedGoogle Scholar
• Wayne, PA. National Committee for Clinical Laboratory Standards (NCCLS). Susceptibility Testing (M100-S11). 2001.
   Google Scholar
• Jugo J, Kennedy R, Crowe MJ, Lamrock G, McClurg RB, Rooney PJ, et al. Trends in bacteraemia on the haematology and oncology units of a UK tertiary referral hospital. J Hosp Infect 2002; 50(1)48–55
   PubMed Web of Science ®Google Scholar
• Escande MC, Herbrecht R. Prospective study of bacteraemia in cancer patients. Results of a French multicentre study. Support Care Cancer 1998; 6: 273–80
   PubMed Web of Science ®Google Scholar
• Maschmeyer G, Braveny I. Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s. Eur J Clin Microbiol Infect Dis 2000; 19: 915–25
   PubMed Web of Science ®Google Scholar
• Sandven P, Bevanger L, Digranes A, Gaustad P, Haukland HH, Steinbakk M. Constant low rate of fungaemia in Norway, 1991 to 1996. The Norwegian Yeast Study Group. J Clin Microbiol 1998; 36: 3455–9
   PubMed Web of Science ®Google Scholar
• Samonis G, Gikas A, Anaissie EJ, Vrenzos G, Maraki S, Tselentis Y, et al. Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans. Antimicrob Agents Chemother 1993; 37(1)51–3
   PubMed Web of Science ®Google Scholar
• Kennedy MJ, Volz PA. Effect of various antibiotics on gastrointestinal colonization and dissemination by Candida albicans. Sabouraudia 1985; 23: 265–73
   PubMedGoogle Scholar
• Pittet D, Li N, Wenzel RP. Association of secondary and polymicrobial nosocomial bloodstream infections with higher mortality. Eur J Clin Microbiol Infect Dis 1993; 12: 813–9
   PubMed Web of Science ®Google Scholar
• Bodey GP. Empirical antibiotic therapy for fever in neutropenic patients. Clin Infect Dis 1993; 17((Suppl 2))S378–84
   PubMed Web of Science ®Google Scholar
• Nucci M, Spector N, Baeno AP, Solza C, Perecmanis T, Becha TC, et al. Risk factors and attributable mortality associated with superinfections in neutropenic patients with cancer. Clin Infect Dis 1997; 24: 575–9
   PubMed Web of Science ®Google Scholar
• Yamamura D, Gucalp R, Carlisle P, Cimino M, Roberts J, Rotstein C. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother 1997; 41: 1704–8
   PubMed Web of Science ®Google Scholar
• Rolston KV, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, et al. A comparison of imipenem to ceftazidime with or without amikacin as empirical therapy in febrile neutropenic patients. Arch Intern Med 1992; 152(2)283–91
   PubMedGoogle Scholar
• Nucci M, Colombo AL. Risk factors for breakthrough candidaemia. Eur J Clin Microbiol Infect Dis 2002; 21: 209–11
   PubMed Web of Science ®Google Scholar
• Jones PG, Rolston KV, Fainstein V, Elting L, Walters RS, Bodey GP. Aztreonam therapy in neutropenic patients with cancer. Am J Med 1986; 81: 243–8
   PubMed Web of Science ®Google Scholar
• Bodey GP, Feld R, Burgess MA. Beta-lactam antibiotics alone or in combination with gentamicin for therapy of Gram-negative bacillary infections in neutropenic patients. Am J Med Sci 1976; 271: 179–86
   PubMed Web of Science ®Google Scholar
• Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001; 357: 1851–3
   PubMed Web of Science ®Google Scholar
• EORTC, Dornbusch K, King A, Legakis N. Incidence of antibiotic resistance in blood and urine isolates from hospitalized patients. Report from a European collaborative study. European Study Group on Antibiotic Resistance (ESGAR). Scand J Infect Dis 1998; 30: 281–8
   PubMedGoogle Scholar
• Verbist L. Epidemiology and sensitivity of 8625 ICU and haematology/oncology bacterial isolates in Europe. International Study Group. Scand J Infect Dis Suppl 1993; 91: 14–24
   PubMedGoogle Scholar
• Carratala J, Alcaide F, Fernandez-Sevilla A, Corbella X, Linares J, Gudiol F. Bacteraemia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin Infect Dis 1995; 20: 1169–73
   PubMed Web of Science ®Google Scholar
• Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994; 13: 50–5
   PubMed Web of Science ®Google Scholar
• Witte W. Antibiotic resistance in Gram-positive bacteria: epidemiological aspects. J Antimicrob Chemother 1999; 44((Suppl A))1–9
   PubMed Web of Science ®Google Scholar
• Fluit AC, Wielders CL, Verhoef J, Schmitz FJ. Epidemiology and susceptibility of 3051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J Clin Microbiol 2001; 39: 3727–32
   PubMed Web of Science ®Google Scholar
• Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994; 330: 1240–1
   PubMed Web of Science ®Google Scholar
• Gomez L, Garau J, Estrada C, Marquez M, Dalmau D, Zercavins M, et al. Ciprofloxacin prophylaxis in patients with acute leukaemia and granulocytopenia in an area with a high prevalence of ciprofloxacin- resistant Escherichia coli. Cancer 2003; 97(2)419–24
   PubMed Web of Science ®Google Scholar
• 2003. NN-V. Usage of Antibacterial Agents and Occurrence of Antimicrobial Resistance in Norway. Tromsø/Oslo 2004, 2004.
   Google Scholar
• Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl 1990; 74: 63–70
   PubMedGoogle Scholar
• Schimpff SC, Gaya H, Klastersky J, Tattersall MH, Zinner SH. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC International Antimicrobial Therapy Project Group. J Infect Dis 1978; 137: 14–29
   PubMedGoogle Scholar
• The Immunocompromized Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis 1990; 161: 397–401
   PubMed Web of Science ®Google Scholar
• Bodey GP, Rolston KV. Management of fever in neutropenic patients. J Infect Chemother 2001; 7: 1–9
   PubMedGoogle Scholar
• Viscoli C. Management of infection in cancer patients. Studies of the EORTC International Antimicrobial Therapy Group (IATG). Eur J Cancer 2002; 38((Suppl 4))82–7
   PubMed Web of Science ®Google Scholar
• Pizzo PA, Ladisch S, Ribichaud K. Treatment of Gram-positive septicaemia in cancer patients. Cancer 1980; 45: 206–7
   PubMed Web of Science ®Google Scholar
• Bochud PY, Calandra T, Francioli P. Bacteraemia due to viridans streptococci in neutropenic patients: a review. Am J Med 1994; 97: 256–64
   PubMed Web of Science ®Google Scholar